Streetbeat News

Price Targets

USB

Goldman Sachs analyst Richard Ramsden has maintained a Neutral rating on U.S. Bancorp (NYSE:USB) and lowered the price target from $41 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 9:29 pm

EFX

Goldman Sachs analyst Andre Benjamin has maintained a Neutral rating on Equifax (NYSE:EFX) and lowered the price target from $232 to $208.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 9:25 pm

C

Goldman Sachs analyst Richard Ramsden has maintained a Neutral rating on Citigroup (NYSE:C) and lowered the price target from $47 to $41.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 9:24 pm

NEE

Goldman Sachs analyst Michael Lapides has maintained a 'Buy' rating on NextEra Energy (NYSE:NEE) but lowered the price target from $83 to $72.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 9:18 pm

LFMD

LifeMD (NASDAQ:LFMD) has received 4 bullish ratings from analysts in the last quarter, with an average 12-month price target of $7.75, up 10.71% from the previous average price target of $7.00.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 9:00 pm

OKTA

In the last quarter, Okta (NASDAQ:OKTA) received 7 bullish, 6 somewhat bullish, and 10 indifferent ratings from analysts. The company's average 12-month price target is $92.87, with a high of $112.00 and a low of $75.00. This average price target has increased by 10.84% over the past month.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 8:00 pm

CELH

Over the past 3 months, 10 analysts have published their opinion on Celsius Holdings (NASDAQ:CELH) stock. The company has an average price target of $198.1 with a high of $250.00 and a low of $155.00. The average price target has increased by 17.02% over the past month.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 8:00 pm

TOST

Mizuho Securities analyst Dan Dolev downgraded Toast Inc (NYSE:TOST) to Neutral from Buy and lowered the price target to $16 from $30. The downgrade is due to the company's muted success in enterprise business, higher reliance on TOST Capital, and potential headwinds from student loan payments leading to declining restaurant spending. The rise of GLP-1 drugs like Ozempic for Americans with Type-2 diabetes and obesity can also curb the company's volumes. The analyst also lowered its FY24 and FY25 gross revenue and adjusted EBITDA estimates.

Portfolio Pulse from Lekha Gupta

October 02, 2023 | 6:55 pm

ZS

Piper Sandler has upgraded Zscaler's stock from Neutral to Overweight and raised its price target from $160 to $190. This has resulted in Zscaler shares trading higher.

Portfolio Pulse from Bill Haddad

October 02, 2023 | 6:26 pm

SEDG

Barclays has downgraded SolarEdge's stock from Overweight to Equal-Weight and reduced its price target from $274 to $152. As a result, SolarEdge shares are trading lower.

Portfolio Pulse from Bill Haddad

October 02, 2023 | 6:22 pm